First of Amgen’s Phase III Sjögren's disease trials succeeds

Amgen is running a second Phase III study of dazodalibep in Sjögren's disease as it eyes a spot in a lacking market. Amgen is running a second Phase III study of dazodalibep in Sjögren's disease as it eyes a spot in a lacking market. Amgen acquired the drug through its $27.8bn buyout of Horizon Therapeutics. Credit: JHVEPhoto / Shutterstock.com Amgen’s Phase III Sjögren’s disease trial has met its primary endpoint, marking the latest sign that the indication could be set for its first-ever drug approvals. In the double-blind, randomised, placebo-controlled Phase III OASIZ 301 study (NCT06104124), patients treated with dazodalibep…

Source: Clinical Trials Arena